

AT THE COMPANY
Donald Hildebrand / Jennifer Nelms
(404) 727-0971 / info@geovax.com

FOR IMMEDIATE RELEASE

Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program

ATLANTA, Ga., February 4, 2008 – GeoVax Labs, Inc. (OTC BB: GOVX), www.geovax.com, an Atlanta based biotechnology company announced the addition of company co-founder Dr. Harriet Robinson to its staff as Vice President of Research & Development. Dr. Robinson is known worldwide for her outstanding work on retrovirus biology and development of DNA vaccines with special emphasis on HIV/AIDS. She has been instrumental in GeoVax's success through her HIV/AIDS vaccine development activities while at Emory University and as Chief Scientific Advisor to GeoVax. Dr. Robinson joined GeoVax part time in Nov. 2007 and will be full time Feb. 15, 2008.

Significant advances by GeoVax's HIV/AIDS vaccine development program have warranted Dr. Robinson's full time participation. By focusing her efforts exclusively at GeoVax, Dr. Robinson intends to speed up the vaccine development and human trial evaluation program required to meet FDA regulatory requirements and future vaccine commercialization efforts. Dr. Robinson stated, "Our AIDS vaccine efforts are rapidly moving forward to a new and exciting level and include plans for initiating Phase 2 human trials in 2008. It's important to me to be able to work full time with the GeoVax team to learn absolutely everything we can from our phase 2 trials so that we appropriately set the stage for phase 3 efficacy trials. I believe in the GeoVax vaccine and want to carry it forward as rapidly and as effectively as possible for worldwide use for the prevention of AIDS."

"As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date," said Don Hildebrand, President, CEO, and Chairman of GeoVax Labs, Inc. "Her leadership in HIV/AIDS vaccine research is invaluable. We believe her contributions will positively impact the lives of millions of people worldwide."

About Dr. Harriet Robinson

Dr. Robinson's laboratory, working with Dr. Bernard Moss's Laboratory at the US National Institutes of Health and researchers at the US Centers for Disease Control, developed the GeoVax's HIV-1 AIDS vaccine technology. She has served as Chief of Microbiology and Immunology at Emory University's Yerkes National Primate Research Center and was an Asa Griggs Candler Professor of Microbiology and Immunology at Emory University School of Medicine.

Dr. Robinson is a pioneer in DNA vaccines and one of the world's leading AIDS vaccine researchers. Research with retroviral vectors led to her pioneering studies with DNA vaccines. Her developmental work with HIV/AIDS vaccines has been guided by the ability of candidate GeoVax vaccines to raise protection against AIDS in non human primate models. In a series of 3 major vaccine trials involving 26 different trial groups, she identified and took forward the vaccine candidates/formulations that provided the best protection. These protection studies led to selection of effective AIDS vaccines to move forward into advanced human clinical trials. Dr. Robinson has published extensively on HIV/AIDS vaccine research, with more than 150 referred scientific journal publications, 50 monograph reviews and six book chapters authored. She has

MORE

consulted for the U.S. National Institutes of Health, the U.S. Food and Drug Administration, the Bill and Melinda Gates Foundation and the World Health Organization.

Dr. Robinson received her B.A. from Swarthmore College and earned her PhD in Microbiology from the Massachusetts Institute of Technology. She has been elected to the American Academy of Microbiology and elected as an "AAAS Fellow" (American Association for the Advancement of Science) where she was recognized for her outstanding work on retrovirus biology and development of DNA vaccines with special emphasis on HIV/AIDS vaccines.

GeoVax Labs, Inc.

GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is covered by 20 issued or filed patent applications. GeoVax HIV/AIDS vaccines are designed to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1. GeoVax HIV/AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage. GeoVax's core HIV/AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax HIV/AIDS vaccines are moving forward in human clinical trials administered by the HIV Vaccine Trials Network (HVTN-Division of the National Institutes of Health). Two (2) human trials have been successfully completed and three (3) human trials involving over 105 individuals are currently ongoing with excellent safety and positive anti-HIV-1 immune responses in the majority of vaccine recipients. GeoVax and the HVTN are currently preparing for very important Phase 2 human trials which are being planned for mid 2008.

About GeoVax DNA & MVA Genetically Engineered HIV/AIDS vaccines:

- Our DNA vaccine "primes" immune responses & MVA vaccine "boosts" immune responses against the AIDS virus
- DNA and MVA vaccines are both genetically engineered vaccines expressing over 50% of the AIDS virus components in the vaccine recipient and can not cause AIDS
- Protected 22 of 23 (96%) non-human primates against AIDS for over 3½ years
- Are manufactured & tested under GMP/GLP – EMEA (EU) and FDA guidelines
- Satisfactorily completed 2 earlier HIV/AIDS vaccine Phase 1 human trials
- Currently have 3 ongoing Phase 1 Human Trials – 1 was initiated in 2006, 2 in summer 2007
- GeoVax HIV/AIDS vaccines have been demonstrated safe to date in human trials
- Demonstrate positive anti-HIV immune responses in majority of human vaccine recipients
- Based on results in Phase 1 trials, are scheduled for Phase 2 trials conducted by the HVTN in mid 2008.

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitations, risks detailed in the Company's Securities and Exchange Commission filings and report.